Earnings call transcripts

Management framed 2025 as another strong growth year, with capacity expansion and shareholder returns offsetting normalization in several 2024 benefits.

Management framed 2025 as a reset toward cost discipline and commercialization, with carbon capture and low-carbon products driving potential upside later this year.

Management framed 2025 as a margin-led execution year, with recovery upside deliberately excluded and FX obscuring operational progress.

Management framed 2024 as completed P&C profit restoration, with 2025 shifting toward scalable growth and more predictable earnings.

Management emphasized contracted load growth, a larger investment runway, and financing discipline while reiterating high-end growth confidence.

Management described improving orders and sequential execution, while making 2025’s $8 EPS target conditional on stronger demand after Q1.

Management framed 2025 around accelerating mortgage customer wins, sustained futures momentum, disciplined investment, and renewed capital returns.

Management framed 2025 as the trough’s end, with improving hospital finances, XT Amplify momentum, and a path toward sustained growth through 2026.

Management reframed the year around worsening China and duty-free headwinds, while stressing resilience, efficiencies and a cautious recovery path beyond FY25.

Management framed 2025 as a controlled reset: inventory and cost execution should offset cyclical pressure, while tariffs remain unmodeled upside or downside.

Management framed the quarter as broad-based execution, with premium smartphones, China demand, and diversification offsetting unresolved licensing and modem uncertainties.

Management portrayed durable pharmaceutical and oncology momentum offset by an unusually soft illness season and cautious Medical-Surgical outlook.